PDF herunterladen
Thromb Haemost 2021; 121(06): 716-730
DOI: 10.1055/s-0040-1721665
Review Article

Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects

A. John Camm
1   Division of Cardiac and Vascular Sciences, Molecular and Clinical Sciences Research Institute, St George's, University of London, London, United Kingdom
,
Dan Atar
2   Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway
3   University of Oslo, Oslo, Norway
› Institutsangaben Funding This study was supported by Bayer.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Multiple randomized controlled trials and many real-world evidence studies have consistently shown that non-vitamin K antagonist oral anticoagulants (NOACs) are preferable to vitamin K antagonists for thromboembolic stroke prevention in the majority of patients with atrial fibrillation (AF). However, their role in the management of patients with AF and comorbidities, as well as in other patient populations with a high risk of stroke, such as patients with prior embolic stroke of undetermined source (ESUS) and those with atherosclerosis, is less clear. There is now increasing evidence suggesting that NOACs have a beneficial effect in the prevention of stroke in patients with AF and comorbidities, such as renal impairment and diabetes. In addition, while studies investigating the efficacy and safety of NOACs for the prevention of secondary stroke in patients with a history of ESUS demonstrated neutral results, subanalyses suggested potential benefits in certain subgroups of patients with ESUS. One NOAC, rivaroxaban, has also recently been found to be effective in reducing the risk of stroke in patients with chronic cardiovascular disease including coronary artery disease and peripheral artery disease, further broadening the patient groups that may benefit from NOACs. In this article, we will review recent evidence for the use of NOACs across the stroke spectrum in detail, and discuss the progress and future prospects in the different stroke areas.

Keywords

stroke prevention - non-vitamin K antagonist oral anticoagulants - atrial fibrillation - embolic stroke of undetermined source - atherosclerosis


Publikationsverlauf

Eingereicht: 16. Juli 2020

Angenommen: 31. Oktober 2020

Artikel online veröffentlicht:
07. Januar 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 World Health Organization, The top 10 causes of death. 2018 . Accessed October 5, 2020 at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
    PubMed
  • 2 Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res 2017; 120 (03) 439-448
    CrossrefPubMedGoogle Scholar
  • 3 Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. Stroke 2009; 40 (06) 2068-2072
    CrossrefPubMedGoogle Scholar
  • 4 Hart RG, Diener HC, Coutts SB. et al; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13 (04) 429-438
    CrossrefPubMedGoogle Scholar
  • 5 Tomek A. Embolic stroke of undetermined source (ESUS). CNS 2018; 4: 92-97
    PubMedGoogle Scholar
  • 6 Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke 2017; 48 (04) 867-872
    CrossrefPubMedGoogle Scholar
  • 7 Kernan WN, Ovbiagele B, Black HR. et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (07) 2160-2236
    CrossrefPubMedGoogle Scholar
  • 8 Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (06) 630S-669S
    CrossrefPubMedGoogle Scholar
  • 9 Lansberg MG, O'Donnell MJ, Khatri P. et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e601S-e636S
    CrossrefPubMedGoogle Scholar
  • 10 Hart RG, Sharma M, Mundl H. et al; NAVIGATE ESUS Investigators. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378 (23) 2191-2201
    CrossrefPubMedGoogle Scholar
  • 11 Diener HC, Sacco RL, Easton JD. et al; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380 (20) 1906-1917
    CrossrefPubMedGoogle Scholar
  • 12 Topcuoglu MA, Liu L, Kim DE, Gurol ME. Updates on prevention of cardioembolic strokes. J Stroke 2018; 20 (02) 180-196
    CrossrefPubMedGoogle Scholar
  • 13 LaMori JC, Mody SH, Gross HJ. et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis 2013; 7 (02) 53-62
    CrossrefPubMedGoogle Scholar
  • 14 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22 (08) 983-988
    CrossrefPubMedGoogle Scholar
  • 15 Kirchhof P, Benussi S, Kotecha D. et al; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 16 Steffel J, Verhamme P, Potpara TS. et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
    CrossrefPubMedGoogle Scholar
  • 17 Adams Jr HP. Secondary prevention of atherothrombotic events after ischemic stroke. Mayo Clin Proc 2009; 84 (01) 43-51
    CrossrefPubMedGoogle Scholar
  • 18 Aboyans V, Ricco JB, Bartelink MEL. et al. Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018; 55 (03) 305-368
    CrossrefPubMedGoogle Scholar
  • 19 Knuuti J, Wijns W, Saraste A. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41 (03) 407-477
    CrossrefPubMedGoogle Scholar
  • 20 Smith Jr SC, Benjamin EJ, Bonow RO. et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124 (22) 2458-2473
    CrossrefPubMedGoogle Scholar
  • 21 Roffi M, Patrono C, Collet JP. et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
    CrossrefPubMedGoogle Scholar
  • 22 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347 (13) 969-974
    CrossrefPubMedGoogle Scholar
  • 23 van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360 (9327): 109-113
    CrossrefPubMedGoogle Scholar
  • 24 Alexander JH, Lopes RD, James S. et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 25 Oldgren J, Budaj A, Granger CB. et al; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32 (22) 2781-2789
    CrossrefPubMedGoogle Scholar
  • 26 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
    CrossrefPubMedGoogle Scholar
  • 27 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
    CrossrefPubMedGoogle Scholar
  • 28 Go AS, Fang MC, Udaltsova N. et al; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 2009; 119 (10) 1363-1369
    CrossrefPubMedGoogle Scholar
  • 29 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 30 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 31 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 32 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 33 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
    CrossrefPubMedGoogle Scholar
  • 34 Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke 2017; 48 (08) 2142-2149
    CrossrefPubMedGoogle Scholar
  • 35 Camm AJ, Amarenco P, Haas S. et al; XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37 (14) 1145-1153
    CrossrefPubMedGoogle Scholar
  • 36 Coleman CI, Briere JB, Fauchier L. et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy 2019; 7 (01) 1574541
    CrossrefPubMedGoogle Scholar
  • 37 Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of non-vitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 2017; 48 (09) 2494-2503
    CrossrefPubMedGoogle Scholar
  • 38 Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69 (23) 2779-2790
    CrossrefPubMedGoogle Scholar
  • 39 Kumar S, Lim E, Covic A. , et al. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol 2019; 74 (17) 2204-2215
    CrossrefPubMedGoogle Scholar
  • 40 Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol 2018; 14 (05) 337-351
    CrossrefPubMedGoogle Scholar
  • 41 Olesen JB, Lip GYH, Kamper AL. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367 (07) 625-635
    CrossrefPubMedGoogle Scholar
  • 42 Yao X, Tangri N, Gersh BJ. et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2017; 70 (21) 2621-2632
    CrossrefPubMedGoogle Scholar
  • 43 Fox KAA, Piccini JP, Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32 (19) 2387-2394
    CrossrefPubMedGoogle Scholar
  • 44 Hijazi Z, Hohnloser SH, Oldgren J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129 (09) 961-970
    CrossrefPubMedGoogle Scholar
  • 45 Hohnloser SH, Hijazi Z, Thomas L. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33 (22) 2821-2830
    CrossrefPubMedGoogle Scholar
  • 46 Bohula EA, Giugliano RP, Ruff CT. et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134 (01) 24-36
    CrossrefPubMedGoogle Scholar
  • 47 Weir MR, Berger JS, Ashton V. et al. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. Curr Med Res Opin 2017; 33 (10) 1891-1900
    CrossrefPubMedGoogle Scholar
  • 48 Coleman CI, Martinez BK, Turpie AGG, Sood N, Bunz TJ, Kreutz R. Effectiveness and safety of rivaroxaban vs. warfarin in patients with nonvalvular atrial fibrillation and moderate-to-severe chronic kidney disease. Blood 2017; 130: 2393
    PubMedGoogle Scholar
  • 49 Bonnemeier H, Huelsebeck M, Kloss S. Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - a retrospective cohort study. Int J Cardiol Heart Vasc 2019; 23: 100367
    CrossrefPubMedGoogle Scholar
  • 50 Bonnemeier H, Kreutz R, Kloss S, Enders D, Häckl D, Schmedt N. Comparative safety and effectiveness of non-vitamin-K oral anticoagulants vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - results from the RELOADED study. Paper presented at: 5th European Stroke Organisation Conference, Milan, Italy, May 22–24,2019. Abstract AS25–066. Accessed October 5, 2020 at: https://journals.sagepub.com/toc/esoa/4/1_suppl
    PubMedGoogle Scholar
  • 51 Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 131 (11) 972-979
    CrossrefPubMedGoogle Scholar
  • 52 Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy 2017; 37 (04) 412-419
    CrossrefPubMedGoogle Scholar
  • 53 Siontis KC, Zhang X, Eckard A. et al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation 2018; 138 (15) 1519-1529
    CrossrefPubMedGoogle Scholar
  • 54 Coleman CI, Kreutz R, Sood NA. et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med 2019; 132 (09) 1078-1083
    CrossrefPubMedGoogle Scholar
  • 55 Chang SH, Wu CV, Yeh YH. et al. Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and stages 4 or 5 chronic kidney disease. Am J Med 2019; 132 (11) 1335-1343.e6
    CrossrefPubMedGoogle Scholar
  • 56 Marti HP, Serebruany V, Atar D. Challenging anticoagulation in advanced renal failure. Am J Med 2019; 132 (11) 1258-1259
    CrossrefPubMedGoogle Scholar
  • 57 Janssen Pharmaceuticals Inc., Xarelto (rivaroxaban): Prescribing Information. 2020 . Accessed October 5, 2020 at: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf
    PubMed
  • 58 Boehringer Ingelheim Pharmaceuticals Inc., Pradaxa ® (dabigatran etexilate): Prescribing Information. 2020 . Accessed October 5, 2020 at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf
    PubMed
  • 59 Daiichi Sankyo Inc., Savaysa ® (edoxaban): Prescribing information. 2020 . Accessed October 5, 2020 at: http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true
    PubMed
  • 60 Bristol-Myers Squibb Company, Pfizer Inc. Eliquis ® (apixaban): Prescribing Information. 2019 . Accessed October 5, 2020 at: http://packageinserts.bms.com/pi/pi_eliquis.pdf
    PubMed
  • 61 Pokorney SD. RENAL-AF: Apixaban vs. warfarin for stroke prevention in patients with end stage renal disease on hemodialysis and AFib. 2019 . Accessed February 4, 2020 at: https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=469e5bd88fff4d2bb8ec183e71521637
    PubMed
  • 62 Atrial Fibrillation Network, Bristol-Myers Squibb, Pfizer, Compare apixaban and vitamin-K antagonists in patients with atrial fibrillation (AF) and end-stage kidney disease (ESKD) (AXADIA). 2019 . Accessed October 5, 2020 at: https://clinicaltrials.gov/ct2/show/NCT02933697
    PubMed
  • 63 St Michael's Hospital, Canadian Institutes of Health Research, Strategies for the management of atrial fibrillation in patients receiving hemodialysis (SAFE-HD). 2019 . Accessed October 5, 2020 at: https://clinicaltrials.gov/ct2/show/NCT03987711
    PubMed
  • 64 Wheeler DS, Giugliano RP, Rangaswami J. Anticoagulation-related nephropathy. J Thromb Haemost 2016; 14 (03) 461-467
    CrossrefPubMedGoogle Scholar
  • 65 Brodsky S, Eikelboom J, Hebert LA. Anticoagulant-related nephropathy. J Am Soc Nephrol 2018; 29 (12) 2787-2793
    CrossrefPubMedGoogle Scholar
  • 66 Posch F, Ay C, Stöger H, Kreutz R, Beyer-Westendorf J. Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost 2019; 3 (02) 207-216
    CrossrefPubMedGoogle Scholar
  • 67 Peeters FECM, Dudink EAMP, Kimenai DM. et al. Vitamin K antagonists, non-vitamin K antagonist oral anticoagulants, and vascular calcification in patients with atrial fibrillation. TH Open 2018; 2 (04) e391-e398
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 68 Di Lullo L, Ronco C, Cozzolino M. et al. Non-vitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thromb Res 2017; 155: 38-47
    CrossrefPubMedGoogle Scholar
  • 69 Brodsky SV, Nadasdy T, Rovin BH. et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80 (02) 181-189
    CrossrefPubMedGoogle Scholar
  • 70 Ryan M, Ware K, Qamri Z. et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant 2014; 29 (12) 2228-2234
    CrossrefPubMedGoogle Scholar
  • 71 van Gorp RH, Schurgers LJ. New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs). Nutrients 2015; 7 (11) 9538-9557
    CrossrefPubMedGoogle Scholar
  • 72 de Aquino Moura KB, Behrens PMP, Pirolli R. et al. Anticoagulant-related nephropathy: systematic review and meta-analysis. Clin Kidney J 2019; 12 (03) 400-407
    CrossrefPubMedGoogle Scholar
  • 73 Brodsky SV, Mhaskar NS, Thiruveedi S. et al. Acute kidney injury aggravated by treatment initiation with apixaban: another twist of anticoagulant-related nephropathy. Kidney Res Clin Pract 2017; 36 (04) 387-392
    CrossrefPubMedGoogle Scholar
  • 74 Shin JI, Luo S, Alexander GC. et al. Direct oral anticoagulants and risk of acute kidney injury in patients with atrial fibrillation. J Am Coll Cardiol 2018; 71 (02) 251-252
    CrossrefPubMedGoogle Scholar
  • 75 Chan YH, Yeh YH, See LC. et al. Acute kidney injury in Asians with atrial fibrillation treated with dabigatran or warfarin. J Am Coll Cardiol 2016; 68 (21) 2272-2283
    CrossrefPubMedGoogle Scholar
  • 76 Chan YH, Yeh YH, Hsieh MY. et al. The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: a nationwide cohort study in Taiwan. Int J Cardiol 2018; 265: 83-89
    CrossrefPubMedGoogle Scholar
  • 77 Klil-Drori AJ, Azoulay L, Nie R, Renoux C, Nessim SJ, Filion KB. Comparative risk of acute kidney injury with oral anticoagulant use among patients with nonvalvular atrial fibrillation. Blood 2017; 130: 700
    CrossrefPubMedGoogle Scholar
  • 78 Coleman CI, Kreutz R, Sood N. et al. Rivaroxaban's impact on renal decline in patients with nonvalvular atrial fibrillation: a US MarketScan claims database analysis. Clin Appl Thromb Hemost 2019; 25 DOI: 1076029619868535.
    CrossrefPubMedGoogle Scholar
  • 79 Bonnemeier H, Kreutz R, Kloss S, Enders D, Häckl D, Schmedt N. Comparative safety and effectiveness of non-vitamin-K oral anticoagulants vs phenprocoumon in patients with non-valvular atrial fibrillation and diabetes - results from the RELOADED study. Paper presented at: 5th European Stroke Organisation Conference. Milan, Italy, 22-24 May 2019, AS25-069. Accessed October 5, 2020 at: https://journals.sagepub.com/toc/esoa/4/1_suppl
    PubMedGoogle Scholar
  • 80 Vaitsiakhovich T, Coleman CI, Kleinjung F. et al. Worsening of renal function in atrial fibrillation patients with stage 3 or 4 chronic kidney disease treated with warfarin or rivaroxaban - evidence from the real-world CALLIPER study in the US claims. European Society of Cardiology Congress. Paris, France, 31 August–5 September 2019, Poster P4746. Accessed October 5, 2020 at: https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz745.1122/5596296?redirectedFrom=fulltext
    PubMedGoogle Scholar
  • 81 Hernandez AV, Bradley G, Khan M. et al. Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. Eur Heart J Qual Care Clin Outcomes 2020; 6 (04) 301-307
    CrossrefPubMedGoogle Scholar
  • 82 GWT-TUD GmbH, ClinStat GmbH, Factor XA - inhibition in renal patients with non-valvular atrial fibrillation - observational registry (XARENO). 2019 . Accessed October 5, 2020 at: https://clinicaltrials.gov/ct2/show/NCT02663076
    PubMed
  • 83 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 2019; 140 (02) e125-e151
    CrossrefPubMedGoogle Scholar
  • 84 De Sensi F, De Potter T, Cresti A, Severi S, Breithardt G. Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. Cardiovasc Diagn Ther 2015; 5 (05) 364-373
    PubMedGoogle Scholar
  • 85 Bhatt DL, Steg PG, Ohman EM. et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295 (02) 180-189
    CrossrefPubMedGoogle Scholar
  • 86 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69 (06) 546-554
    CrossrefPubMedGoogle Scholar
  • 87 Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GYH. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012; 141 (01) 147-153
    CrossrefPubMedGoogle Scholar
  • 88 Fangel MV, Nielsen PB, Larsen TB. et al. Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: a Danish nationwide cohort study. Int J Cardiol 2018; 268: 137-142
    CrossrefPubMedGoogle Scholar
  • 89 Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non-vitamin K antagonist oral anticoagulants: a review. JAMA Cardiol 2017; 2 (04) 442-448
    CrossrefPubMedGoogle Scholar
  • 90 Wang A, Green JB, Halperin JL, Piccini Sr JP. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol 2019; 74 (08) 1107-1115
    CrossrefPubMedGoogle Scholar
  • 91 American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care 2019; 42 (Suppl. 01) S103-S123
    CrossrefPubMedGoogle Scholar
  • 92 Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis 2018; 25 (02) 121-132
    CrossrefPubMedGoogle Scholar
  • 93 Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes 2007; 25: 90-97
    CrossrefPubMedGoogle Scholar
  • 94 Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41 (01) 1-12
    CrossrefPubMedGoogle Scholar
  • 95 Middleton RJ, Foley RN, Hegarty J. et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006; 21 (01) 88-92
    CrossrefPubMedGoogle Scholar
  • 96 Hertig A, Rondeau E. Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury. J Am Soc Nephrol 2004; 15 (04) 844-853
    CrossrefPubMedGoogle Scholar
  • 97 Farquhar A, MacDonald MK, Ireland JT. The role of fibrin deposition in diabetic glomerulosclerosis: a light, electron and immunofluorescence microscopy study. J Clin Pathol 1972; 25 (08) 657-667
    CrossrefPubMedGoogle Scholar
  • 98 Tanaka M, Arai H, Liu N. et al. Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation. Kidney Int 2005; 67 (06) 2123-2133
    CrossrefPubMedGoogle Scholar
  • 99 Sumi A, Yamanaka-Hanada N, Bai F, Makino T, Mizukami H, Ono T. Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice. Biol Pharm Bull 2011; 34 (06) 824-830
    CrossrefPubMedGoogle Scholar
  • 100 Amdur RL, Feldman HI, Gupta J. et al; CRIC Study Investigators. Inflammation and progression of CKD: the CRIC study. Clin J Am Soc Nephrol 2016; 11 (09) 1546-1556
    CrossrefPubMedGoogle Scholar
  • 101 Afkarian M, Sachs MC, Kestenbaum B. et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013; 24 (02) 302-308
    CrossrefPubMedGoogle Scholar
  • 102 Ezekowitz JA, Lewis BS, Lopes RD. et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother 2015; 1 (02) 86-94
    CrossrefPubMedGoogle Scholar
  • 103 Brambatti M, Darius H, Oldgren J. et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol 2015; 196: 127-131
    CrossrefPubMedGoogle Scholar
  • 104 Bansilal S, Bloomgarden Z, Halperin JL. et al; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J 2015; 170 (04) 675.e8-682.e8
    CrossrefPubMedGoogle Scholar
  • 105 Plitt A, Ruff CT, Goudev A. et al. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Int J Cardiol 2020; 304: 185-191
    CrossrefPubMedGoogle Scholar
  • 106 Coleman CI, Bunz TJ, Eriksson D, Meinecke AK, Sood NA. Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. Diabet Med 2018; 35 (08) 1105-1110
    CrossrefPubMedGoogle Scholar
  • 107 Baker WL, Beyer-Westendorf J, Bunz TJ. et al. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. Diabetes Obes Metab 2019; 21 (09) 2107-2114
    CrossrefPubMedGoogle Scholar
  • 108 Bayer AG. Xarelto ® (rivaroxaban): summary of product characteristics. 2020 . Accessed July 30, 2020 at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf
    PubMed
  • 109 Bristol Myers Squibb, Pfizer, Eliquis® (apixaban): summary of product characteristics. 2020 . Accessed July 30, 2020 at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf
    PubMed
  • 110 Boehringer Ingelheim International GmbH, Pradaxa® (dabigatran etexilate): summary of product characteristics. 2020 . Accessed September 8, 2020 at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
    PubMed
  • 111 Daiichi Sankyo Europe Gmb H. Lixiana® (edoxaban): summary of product characteristics. 2019 . Accessed April 9, 2020 at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf
    PubMed
  • 112 Steinberg BA, Shrader P, Thomas L. et al; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol 2016; 68 (24) 2597-2604
    CrossrefPubMedGoogle Scholar
  • 113 Steinberg BA, Shrader P, Pieper K. et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT, ‐AF) II Investigators. Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 2018; 7 (04) e007633
    CrossrefPubMedGoogle Scholar
  • 114 Atar D, Grundvold I. On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?. Eur Heart J 2019; 40 (19) 1501-1503
    CrossrefPubMedGoogle Scholar
  • 115 Lowres N, Giskes K, Hespe C, Freedman B. Reducing stroke risk in atrial fibrillation: adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal. Korean Circ J 2019; 49 (10) 883-907
    CrossrefPubMedGoogle Scholar
  • 116 Geisler T, Poli S, Meisner C. et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke 2017; 12 (09) 985-990
    CrossrefPubMedGoogle Scholar
  • 117 Kamel H, Longstreth Jr WT, Tirschwell DL. et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods. Int J Stroke 2019; 14 (02) 207-214
    CrossrefPubMedGoogle Scholar
  • 118 Healey JS, Gladstone DJ, Swaminathan B. et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol 2019; 76 (07) 764-773
    CrossrefPubMedGoogle Scholar
  • 119 Ntaios G, Perlepe K, Lambrou D. et al. Prevalence and overlap of potential embolic sources in patients with embolic stroke of undetermined source. J Am Heart Assoc 2019; 8 (15) e012858
    CrossrefPubMedGoogle Scholar
  • 120 University of Thessaly, University of Lausanne, University of Athens, Prediction of AF in ESUS (AF-ESUS). 2019 . Accessed October 5, 2020 at: https://clinicaltrials.gov/ct2/show/NCT02766205
    PubMed
  • 121 University of British Columbia, Boehringer Ingelheim, Thirty day heart monitoring for detection of atrial fibrillation among cryptogenic stroke patients (PROPhecy). 2019 . Accessed October 5, 2020 at: https://clinicaltrials.gov/ct2/show/NCT03712865
    PubMed
  • 122 Ntaios G. Embolic stroke of undetermined source: JACC review topic of the week. J Am Coll Cardiol 2020; 75 (03) 333-340
    CrossrefPubMedGoogle Scholar
  • 123 Sharma M, Hart RG, Connolly SJ. et al. Stroke outcomes in the COMPASS trial. Circulation 2019; 139 (09) 1134-1145
    CrossrefPubMedGoogle Scholar
  • 124 Alexander JH, Becker RC, Bhatt DL. et al; APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119 (22) 2877-2885
    CrossrefPubMedGoogle Scholar
  • 125 Perera KS, Ng KKH, Nayar S. et al. Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial. JAMA Neurol 2020; 77 (01) 43-48
    CrossrefPubMedGoogle Scholar
  • 126 Ferreira JP, Girerd N, Gregson J. et al; High-Risk Myocardial Infarction Database Initiative. Stroke risk in patients with reduced ejection fraction after myocardial infarction without atrial fibrillation. J Am Coll Cardiol 2018; 71 (07) 727-735
    CrossrefPubMedGoogle Scholar
  • 127 Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015; 314 (10) 1030-1038
    CrossrefPubMedGoogle Scholar
  • 128 Zannad F, Anker SD, Byra WM. et al; COMMANDER HF Investigators. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018; 379 (14) 1332-1342
    CrossrefPubMedGoogle Scholar
  • 129 Mehra MR, Vaduganathan M, Fu M. et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J 2019; 40 (44) 3593-3602
    CrossrefPubMedGoogle Scholar